Pharmaceutical

Coherus offloads Humira biosimilar Yusimry for $40m

Hong Kong King-Friend Industrial has acquired worldwide rights to Yusimry, and its subsidiary, Meitheal, will market the therapy in the US.

Jun 30, 2024 - 04:00
Coherus offloads Humira biosimilar Yusimry for $40m
Hong Kong King-Friend Industrial has acquired worldwide rights to Yusimry, and its subsidiary, Meitheal, will market the therapy in the US.
Read the original article

Tags:

Previous Article

Amylyx ventures into metabolic diseases market with $35.1m deal

Next Article

Can routinely collected primary care data drive life sciences investment in the UK?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Hiring activity in the European pharma industry decreas...

Oct 19, 2023

EMA CHMP endorses Mirum Pharmaceuticals’ LIVMARLI for PFIC

EMA CHMP endorses Mirum Pharmaceuticals’ LIVMARLI for PFIC

Jun 4, 2024

STAT+: KalVista pill reduces swelling symptoms caused by genetic disease, achieving goal of late-stage study

STAT+: KalVista pill reduces swelling symptoms caused b...

Feb 13, 2024